| First Author | Kusminski CM | Year | 2020 |
| Journal | Diabetes | Volume | 69 |
| Issue | 3 | Pages | 313-330 |
| PubMed ID | 31882562 | Mgi Jnum | J:285363 |
| Mgi Id | MGI:6392590 | Doi | 10.2337/db19-0327 |
| Citation | Kusminski CM, et al. (2020) A Novel Model of Diabetic Complications: Adipocyte Mitochondrial Dysfunction Triggers Massive beta-Cell Hyperplasia. Diabetes 69(3):313-330 |
| abstractText | Obesity-associated type 2 diabetes mellitus (T2DM) entails insulin resistance and loss of beta-cell mass. Adipose tissue mitochondrial dysfunction is emerging as a key component in the etiology of T2DM. Identifying approaches to preserve mitochondrial function, adipose tissue integrity, and beta-cell mass during obesity is a major challenge. Mitochondrial ferritin (FtMT) is a mitochondrial matrix protein that chelates iron. We sought to determine whether perturbation of adipocyte mitochondria influences energy metabolism during obesity. We used an adipocyte-specific doxycycline-inducible mouse model of FtMT overexpression (FtMT-Adip mice). During a dietary challenge, FtMT-Adip mice are leaner but exhibit glucose intolerance, low adiponectin levels, increased reactive oxygen species damage, and elevated GDF15 and FGF21 levels, indicating metabolically dysfunctional fat. Paradoxically, despite harboring highly dysfunctional fat, transgenic mice display massive beta-cell hyperplasia, reflecting a beneficial mitochondria-induced fat-to-pancreas interorgan signaling axis. This identifies the unique and critical impact that adipocyte mitochondrial dysfunction has on increasing beta-cell mass during obesity-related insulin resistance. |
